Progress of research on the mechanism of activin A in vascular calcification of chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2022.06.010

Abstract

Abstract:

Vascular calcification (VC) is a common complication of chronic kidney disease (CKD). It can significantly increase the incidence of cardiovascular events and mortality of patients with CKD. More and more studies have shown that activin A, a member of the transforming growth factor β superfamily, is not only involved in the development of VC in patients with CKD, but also a target of the common pathway of both VC and bone metabolism. Antagonists of activin A may have the effect of delaying the progression of CKD and its complications. This article reviewed the mechanism of activin A involved in vascular calcification in CKD, aiming to provide new ideas for the diagnosis, treatment, and prevention of VC in CKD.

Key words: Activin A, Chronic kidney disease, Vascular calcification, Mechanism, Signal transduction

Shan Luo, Santao Ou. Progress of research on the mechanism of activin A in vascular calcification of chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(06): 353-356.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.06.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I06/353

Figures/Tables 1

References 29

[1]	Waziri B, Duarte R, Naicker S. Chronic kidney disease-mineral and bone disorder (CKD-MBD): current perspectives [J]. Int J Nephrol Renovasc Dis, 2019, 12: 263-276.
[2]	Nordholm A, Egstrand S, Gravesen E, et al. Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats [J]. Pflugers Arch, 2019, 471(8): 1079-1094.
[3]	Agapova OA, Fang Y, Sugatani T, et al. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease [J]. Kidney Int, 2016, 89(6): 1231-1243.
[4]	Williams MJ, Sugatani T, Agapova OA, et al. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease [J]. Kidney Int, 2018, 93(1): 147-158.
[5]	Ling N, Ying S, Ueno N, et al. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin [J]. Nature, 1986, 321(6072): 779-782.
[6]	Bloise E, Ciarmela P, Dela Cruz C, et al. Activin A in mammalian physiology [J]. Physiol Rev, 2019, 99(1): 739-780.
[7]	Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival [J]. Cell, 2010, 142(4): 531-543.
[8]	Hénaut L, Chillon JM, Kamel S, et al. Updates on the mechanisms and the care of cardiovascular calcification in chronic kidney disease [J]. Semin Nephrol, 2018, 38(3): 233-250.
[9]	Ma WQ, Sun XJ, Wang Y, et al. Restoring mitochondrial biogenesis with metformin attenuates β-GP-induced phenotypic transformation of VSMCs into an osteogenic phenotype via inhibition of PDK4/oxidative stress-mediated apoptosis [J]. Mol Cell Endocrinol, 2019, 479: 39-53.
[10]	Yonata A, Ali Z, Indrajaya T, et al. The association between the activin A serum level and carotid intima-media thickness in chronic kidney disease patients [J]. Int J Nephrol, 2020, 2020: 8893653.
[11]	Liao R, Wang L, Li J, et al. Vascular calcification is associated with Wnt-signaling pathway and blood pressure variability in chronic kidney disease rats [J]. Nephrology (Carlton), 2020, 25(3): 264-272.
[12]	Román-García P, Carrillo-López N, Fernández-Martín JL, et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression [J]. Bone, 2010, 46(1): 121-128.
[13]	Cai T, Sun D, Duan Y, et al. WNT/β-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression [J]. Exp Cell Res, 2016, 345(2): 206-217.
[14]	Liu J, Zhang L, Zhou Y, et al. Aberrant activation of Wnt pathways in arteries associates with vascular calcification in chronic kidney disease [J]. Int Urol Nephrol, 2016, 48(8): 1313-1319.
[15]	Fang Y, Ginsberg C, Seifert M, et al. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder [J]. J Am Soc Nephrol, 2014, 25(8): 1760-1773.
[16]	Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and Klotho [J]. Bone, 2017, 100: 87-93.
[17]	Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease [J]. J Am Soc Nephrol, 2011, 22(1): 124-136.
[18]	Tyson J, Bundy K, Roach C, et al. Mechanisms of the osteogenic switch of smooth muscle cells in vascular calcification: WNT signaling, BMPs, mechanotransduction, and EndMT [J]. Bioengineering (Basel), 2020, 7(3): 88.
[19]	Jackson AO, Zhang J, Jiang Z, et al. Endothelial-to-mesenchymal transition: a novel therapeutic target for cardiovascular diseases [J]. Trends Cardiovasc Med, 2017, 27(6): 383-393.
[20]	Cheng SL, Shao JS, Behrmann A, et al. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells [J]. Arterioscler Thromb Vasc Biol, 2013, 33(7): 1679-1689.
[21]	Hénaut L, Massy ZA. New insights into the key role of interleukin 6 in vascular calcification of chronic kidney disease [J]. Nephrol Dial Transplant, 2018, 33(4): 543-548.
[22]	Bhatt PM, Lewis CJ, House DL, et al. Increased Wnt5a mRNA expression in advanced atherosclerotic lesions, and oxidized LDL treated human monocyte-derived macrophages [J]. Open Circ Vasc J, 2012, 5: 1-7.
[23]	熊琳，朱婷婷，张丽玲，等. 慢性肾病大鼠血管钙化与骨代谢标志物的相关性研究[J]. 中国比较医学，2021, 31(1): 87-94.
[24]	Sugatani T, Agapova OA, Fang Y, et al. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease [J]. Kidney Int, 2017, 91(1): 86-95.
[25]	Baroncelli M, Drabek K, Eijken M, et al. Two-day-treatment of activin-A leads to transient change in SV-HFO osteoblast gene expression and reduction in matrix mineralization [J]. J Cell Physiol, 2020, 235(5): 4865-4877.
[26]	Perens EA, Hoffman HM, Mak RH. Activin A signaling provides an interorgan link between kidney and muscle in CKD-associated muscle wasting [J]. Am J Kidney Dis, 2022, 79(2): 302-304.
[27]	Bataille S, Dou L, Bartoli M, et al. Mechanisms of myostatin and activin A accumulation in chronic kidney disease [J]. Nephrol Dial Transplant, 2022, 37(7): 1249-1260.
[28]	Solagna F, Tezze C, Lindenmeyer MT, et al. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs [J]. J Clin Invest, 2021, 131(11): e135821.
[29]	Cappellini MD, Porter J, Origa R, et al. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study [J]. Haematologica, 2019, 104(3): 477-484.

Please choose a citation manager

Content to export